Based on inventions from Harvard and Dana-Farber Cancer Institute, Neomorph was launched earlier this year with the support of Deerfield Management.
Neomorph, a US-based protein degradation drug developer spun out of Harvard Medical School (HMS) and Dana-Farber Cancer Institute, has received $109m in series A funding from undisclosed investors.
Neomorph’s approach relies on a technique called molecular glue to trigger protein degradation in disease-habouring targets. It claims the approach can reach proteins that are currently inaccessible because they lack a binding pocket.
The series A funding will help finetune the approach and expand Neomorph’s research personnel as it prepares…
